| scholarly article | Q13442814 |
| P2093 | author name string | Agnieszka Swiatecka-Urban | |
| Johannes Hofer | |||
| Ronald Jaffe | |||
| Riha Bhatt | |||
| Yosuke Miyashita | |||
| Michael Moritz | |||
| Heidi Griffiths | |||
| Tennille N Webb | |||
| P2860 | cites work | Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study | Q43684198 |
| Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. | Q46397604 | ||
| Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? | Q46954291 | ||
| The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. | Q54445554 | ||
| The development of atypical hemolytic uremic syndrome is not influenced by thrombophilia susceptibility factors | Q81064802 | ||
| The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease | Q83909577 | ||
| Hyperhomocysteinemia and related genetic polymorphisms correlate with ulcerative colitis in Chinese Han population in Central China [corrected] | Q84987757 | ||
| Atypical hemolytic uremic syndrome | Q21202864 | ||
| Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome | Q24337607 | ||
| Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype | Q24613907 | ||
| The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10 | Q24620635 | ||
| Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy | Q33344059 | ||
| Acute colitis resembling ulcerative colitis in the hemolytic-uremic syndrome | Q33346569 | ||
| Ischemic colitis as a manifestation of thrombotic microangiopathy following bone marrow transplantation. | Q33358489 | ||
| Cobalamin C defect associated with hemolytic-uremic syndrome | Q33366622 | ||
| Thrombomodulin mutations in atypical hemolytic-uremic syndrome | Q33385474 | ||
| Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles | Q33385583 | ||
| Atypical hemolytic-uremic syndrome | Q33386736 | ||
| Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. | Q33393238 | ||
| Acute kidney injury in pregnancy: the thrombotic microangiopathies | Q33393690 | ||
| Atypical hemolytic-uremic syndrome related to abnormalities within the complement system | Q33394393 | ||
| STEC-HUS, atypical HUS and TTP are all diseases of complement activation | Q33403359 | ||
| Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies | Q33403607 | ||
| Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome | Q33408211 | ||
| Dynamics of complement activation in aHUS and how to monitor eculizumab therapy | Q33416519 | ||
| Hemolytic uremic syndrome following bone marrow transplantation: a case report and review of the literature | Q33429362 | ||
| Hemolytic-uremic syndrome mimicking ulcerative colitis. Lack of early diagnostic laboratory findings | Q33479772 | ||
| Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria | Q37098212 | ||
| Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease | Q39951547 | ||
| P433 | issue | 5 | |
| P921 | main subject | atypical hemolytic uremic syndrome | Q17165460 |
| P304 | page(s) | 105-112 | |
| P577 | publication date | 2015-06-19 | |
| P1433 | published in | International journal of medical and pharmaceutical case reports | Q27726121 |
| P1476 | title | Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab | |
| P478 | volume | 4 |
| Q33705135 | Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab |
| Q43213346 | Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab |
| Q91942246 | Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients |
| Q64975120 | Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. |
| Q90087118 | Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease |
Search more.